This review provides a perspective on the Age-related Eye Disease Study 2 (AREDS2) including a summary of the goals and rationale of the study, major findings, subsequent management recommendations, and questions that remain to be answered.
INTRODUCTION
Age-related macular degeneration (AMD) is the leading cause of blindness in developed countries [1, 2] . An estimated 21 million individuals are affected worldwide, and as the population ages, these numbers are projected to increase significantly [3] . The introduction of intravitreal therapies targeted at inhibition of vascular endothelial growth factor (VEGF) has provided effective treatment for the neovascular form of AMD [4] . At present, no such therapy exists for the atrophic form of AMD [5] . In the original Age-related Eye Disease Study (AREDS), supplements containing vitamin C, vitamin E, b-carotene, and zinc were shown to reduce the 5-year likelihood of developing advanced AMD by an estimated 25% in at-risk individuals [6] . Furthermore, this treatment effect persisted in those who continued to be monitored at the 5 year time point following cessation of this controlled, randomized, clinical trial [7 & ]. The Age-related Eye Disease Study 2 (AREDS2) was designed to further investigate whether inclusion of lutein/zeaxanthin and/or omega-3 long-chain polyunsaturated fatty acids (LCPUFAs) to the original AREDS formulation would additionally reduce the risk for progression to advanced AMD. The present review summarizes the goals and rationale for undertaking the AREDS2, significant findings, treatment recommendations, and questions that remain to be answered.
PERSPECTIVE ON THE AGE-RELATED EYE DISEASE STUDY 2: GOALS AND RATIONALE
The AREDS2 is a large, multicentered, phase III, randomized, double-masked, placebo-controlled, 2 Â 2 factorial-designed clinical trial [8 && ]. The primary goal of the AREDS2 was to evaluate the efficacy and safety of lutein plus zeaxanthin and/ or omega-3 LCPUFA supplementation in reducing the risk of developing advanced AMD. The study also aimed to investigate the effects of omitting b-carotene and reducing the concentration of zinc from the original AREDS formulation.
The rationale for including lutein/zeaxanthin and/or omega-3 LCPUFAs in AREDS supplements originated from observational studies that suggested a link between higher dietary consumption of these compounds and decreased risk of developing advanced AMD [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . This association was known at the start of the original AREDS, and lutein was considered for the initial formulation; however, it was not commercially available at the time. A second reason for supplementation with lutein and zeaxanthin is that both are major constituents comprising the macular pigment. The antioxidative properties of these compounds, as well as their ability to reduce exposure to harmful ultra-violet light, may protect the outer retina and retinal pigment epithelium from oxidative stress and contribute to cell membrane stability [20, 21] . In a small prospective study, functional improvement was observed in the multifocal electroretinograms of 15 AMD patients treated with oral supplementation with lutein and zeaxanthin compared with agematched controls [22] .
A second randomization in the AREDS2 evaluated the effect of removing b-carotene and/or lowering the level of zinc from that found in the original AREDS formulation. The rationale for removing bcarotene was secondary to reports that suggested an increased risk for developing lung cancer in cigarette smokers taking supplements containing b-carotene [23, 24] . The reasoning behind lowering zinc levels was that although a dose of 80 mg was used in the original AREDS formulation based on a prior trial suggesting efficacy, there was also evidence to suggest that the maximal level absorbed was closer to 25 mg [25, 26] .
For its primary analysis, the AREDS2 enrolled 4203 participants, ages 50-85 years, between October 17, 2006 and September 28, 2008 , at 82 clinical sites across the United States [8 && ]. Participants were considered at risk for developing advanced AMD in that 66% had bilateral large drusen and 34% had large drusen and advanced AMD in one eye [8 && ]. In addition to taking the original or a variation of the first-generation AREDS supplements, participants were randomly assigned, with equal probability, in a factorial design to receive one of four study formulations daily: placebo; lutein (10 mg)/zeaxanthin (2 mg); omega-3 LCPUFAs, specifically docosahexaenoic acid (DHA, 350 mg) and eicosapentaenoic acid (EPA, 650 mg); or both lutein/zeaxanthin and DHA/EPA (Table 1) .
Of the 4203 participants, 3036 (72%) agreed to a secondary randomization, which aimed to evaluate the effect of eliminating b-carotene and reducing the zinc level from that found in the original AREDS supplements. The four alternative formulations
KEY POINTS
The AREDS2 is a large, multicentered, phase III, randomized, double-masked, placebo-controlled clinical trial the primary goal of which was to evaluate the efficacy and safety of lutein plus zeaxanthin and/or omega-3 LCPUFA supplementation in reducing the risk of developing advanced AMD and also to investigate the effects of omitting b-carotene and reducing the concentration of zinc from the original AREDS formulation.
Although primary analysis of the AREDS2 data did not reveal a clear benefit of daily supplementation with lutein/zeaxanthin and/or omega-3 LCPUFAs (DHA/ EPA) on AMD progression, secondary exploratory analyses did suggest that lutein/zeaxanthin were helpful in reducing this risk.
Questions still remain regarding the AREDS2 study results such as: whether or not the findings can be generalized to the population as a whole, what is the long-term safety profile of supplementation with lutein/ zeaxanthin, which other carotenoids should be included in AREDS-type supplements, and do we have the optimal doses?
were the AREDS formulation (vitamin C, 500 mg; vitamin E, 400 IU; b-carotene, 15 mg; zinc oxide, 80 mg; and cupric oxide, 2 mg), the AREDS formulation minus b-carotene, the AREDS formulation with low zinc (25 mg), or the AREDS formulation minus b-carotene and including low zinc (Table 2) [27 && ]. Owing to the concern for increased risk of lung cancer associated with exposure to b-carotene supplementation, current smokers and former smokers who had discontinued tobacco use within 1 year prior to randomization were assigned to one of the two arms that excluded b-carotene.
Individuals were followed at annual study visits, which included a comprehensive eye examination with best-corrected visual acuity testing using an electronic version of the Early Treatment Diabetic Retinopathy Study technique. Standardized, stereoscopic fundus photographs were obtained at each visit. Individuals were also contacted by telephone 6 months between visits and 3 months following randomization to obtain information on AMD treatment (e.g., the need for intravitreal therapy) and adverse events. The main outcome measure of the AREDS2 was documented development of advanced AMD based on central, masked grading of annual fundus photographs or by treatment history.
SUMMARY OF MAJOR FINDINGS FROM AGE-RELATED EYE DISEASE STUDY 2
In its primary analysis, the AREDS2 demonstrated no beneficial or harmful effect of adding lutein/ zeaxanthin, omega-3 LCPUFAs, or the combination on the progression to advanced AMD or changes in visual acuity compared with placebo [28 && ].
Lutein/zeaxanthin versus b-carotene
In a secondary exploratory analysis, individuals randomized to lutein/zeaxanthin and the AREDS formulation without b-carotene (n ¼ 1114 eyes) were compared with those assigned to no lutein/ zeaxanthin and the original AREDS formulation containing b-carotene (n ¼ 1117 eyes). In this analysis, the hazard ratios were 0. Progression to advanced age-related macular degeneration based on age-related macular degeneration status at enrollment
When secondary exploratory analysis was limited to those eyes with bilateral large drusen at the study 
RECOMMENDATIONS
The AREDS2 is a large, multicentered, placebo-controlled, randomized clinical trial of individuals at risk for developing advanced AMD. In its primary analyses, daily additional supplementation with lutein/zeaxanthin and omega-3 LCPUFAs (DHA/ EPA) combined with modified versions of the original AREDS formulation were not shown to further reduce the risk of progression to advanced AMD or to change visual acuity [28 && ]. However, because of the potential risk of increased incidence of lung cancer in present and former smokers taking b-carotene supplements, AREDS2 and other studies suggested that lutein/zeaxanthin could be a safer carotenoid substitute to b-carotene in AREDS-type supplements [27 && ]. Based on the potential risks of b-carotene supplementation balanced with its possible benefits, which were only demonstrated in exploratory subgroup analysis, substitution with lutein/zeaxanthin in AREDS supplements for b-carotene may be appropriate. Given the valid safety concerns in current and former smokers, it is important to have an AREDS-type formulation available to individuals, which does not contain b-carotene. In the AREDS2 comparison of low-dose (25 mg) to the higher-dose zinc (80 mg) used in the original AREDS formulation, there was no statistically significant effect, and there was insufficient evidence to provide a meaningful clinical recommendation [28 && ].
UNANSWERED QUESTIONS
One limitation of AREDS2 is that several of the reported results are based upon secondary exploratory analyses in the setting of negative primary findings. That is, the AREDS2 primary study results did not clearly demonstrate either a beneficial or harmful effect of including lutein/zeaxanthin and/or omega-3 LCPUFAs; however, secondary exploratory analyses did suggest that lutein/zeaxanthin reduced the risk for progression to advanced AMD [27 && ]. It is important to note that individuals studied in AREDS2 were well nourished and characterized by above-average intake of dietary nutrients [ 
CONCLUSION
In the era of preventive medicine, large-scale, multicentered, placebo-controlled, randomized clinical trials, like the AREDS2, have been invaluable in studying potential therapies, which may help to reduce the risk of progression to advanced AMD. Although primary analysis of the AREDS2 data did not reveal a clear benefit of daily supplementation with lutein/zeaxanthin and/or omega-3 LCPUFAs (DHA/EPA) on AMD progression, secondary exploratory analyses did suggest that lutein/zeaxanthin were helpful in reducing this risk. Given this fact, along with safety concerns related to b-carotene supplementation, the totality of evidence on beneficial and adverse effects from AREDS2 and other studies suggests that lutein/zeaxanthin could be more appropriate than b-carotene in AREDS-type supplements.
